KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) EBIT (2016 - 2025)

Historic EBIT for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to -$321.0 million.

  • Bristol Myers Squibb's EBIT rose 7494.15% to -$321.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 billion, marking a year-over-year increase of 6475.69%. This contributed to the annual value of -$22.3 billion for FY2024, which is 89187.75% down from last year.
  • Per Bristol Myers Squibb's latest filing, its EBIT stood at -$321.0 million for Q3 2025, which was up 7494.15% from -$1.6 billion recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year EBIT high stood at $204.0 million for Q1 2023, and its period low was -$14.4 billion during Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's EBIT had a median value of -$762.0 million in 2022 and averaged -$1.6 billion.
  • In the last 5 years, Bristol Myers Squibb's EBIT surged by 12602.04% in 2023 and then crashed by 718235.29% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's EBIT (Quarter) stood at -$498.0 million in 2021, then plummeted by 47.39% to -$734.0 million in 2022, then plummeted by 45.91% to -$1.1 billion in 2023, then tumbled by 332.96% to -$4.6 billion in 2024, then surged by 93.08% to -$321.0 million in 2025.
  • Its EBIT was -$321.0 million in Q3 2025, compared to -$1.6 billion in Q2 2025 and -$62.0 million in Q1 2025.